Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07634562 Freeze-dried Human Anti-D(Rho) Immunoglobulin(Takeda) liver function failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07634562 clinical trial report covering Freeze-dried Human Anti-D(Rho) Immunoglobulin(Takeda), Phase 1/2, endpoints, sponsor, geography, readout timing
Latest Hotspot
8 min read
NCT07638787 Polatuzumab Vedotin-Piiq High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07638787 clinical trial report covering Polatuzumab Vedotin-Piiq, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07640425 CNT-201 Finger arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640425 clinical trial report covering CNT-201, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07638813 YT-023 Frontotemporal Dementia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07638813 clinical trial report covering YT-023, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07638332 LB-DTK-BKV Hemorrhagic cystitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07638332 clinical trial report covering LB-DTK-BKV, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07637851 Ubamatamab Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07637851 clinical trial report covering Ubamatamab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641036 Fludarabine Phosphate Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641036 clinical trial report covering Fludarabine Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126590 N-3C01 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126590 clinical trial report covering N-3C01, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641426 CID-103 Renal transplant rejection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641426 clinical trial report covering CID-103, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641140 LY-M003 Hepatolenticular Degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641140 clinical trial report covering LY-M003, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07640984 JR-446 Mucopolysaccharidosis III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640984 clinical trial report covering JR-446, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07642635 Semaglutide (Novo Nordisk) Muscular Dystrophy, Duchenne Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642635 clinical trial report covering Semaglutide (Novo Nordisk), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space